Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 82.25
-0.10 (-0.12%)
Jul 9, 2025, 4:08 PM HKT
Innovent Biologics Revenue
In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.
Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
14.04
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
140.77B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Innovent Biologics News
- 9 days ago - Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide - Seeking Alpha
- 9 days ago - Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms - PRNewsWire
- 12 days ago - Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PRNewsWire
- 14 days ago - Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions - PRNewsWire
- 16 days ago - Neutral On Innovent Biologics: Hard To Justify Its Premium - Seeking Alpha
- 17 days ago - Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions - PRNewsWire
- 23 days ago - Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China - PRNewsWire
- 26 days ago - Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions - PRNewsWire